Skip to main content

Lee Yuchun's Form 4 filing

Vertex Pharmaceuticals Inc (VRTX) · filed Apr 8, 2022

Accession no.
0000899243-22-014367
Filed
Apr 8, 2022
Trade date
Apr 6-7, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 11 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.09M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Lee YuchunCIK 0001334365Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 6, 2022Common StockMOption exerciseAcquired+2,000$81.54+$163,0803,875Direct
Apr 6, 2022Common StockSSaleDisposed−17$267.57−$4,548.693,858Direct
Apr 6, 2022Common StockSSaleDisposed−300$270.67F2,F3−$81,2013,558Direct
Apr 6, 2022Common StockSSaleDisposed−1,600$271.78F2,F4−$434,8481,958Direct
Apr 6, 2022Common StockSSaleDisposed−83$272.84F2,F5−$22,645.721,875Direct
Apr 7, 2022Common StockMOption exerciseAcquired+2,000$81.54+$163,0803,875Direct
Apr 7, 2022Common StockSSaleDisposed−417$272.76F2,F7−$113,740.923,458Direct
Apr 7, 2022Common StockSSaleDisposed−500$273.78F2,F8−$136,8902,958Direct
Apr 7, 2022Common StockSSaleDisposed−256$275.26F2,F9−$70,466.562,702Direct
Apr 7, 2022Common StockSSaleDisposed−727$276.37F2,F10−$200,920.991,975Direct
Apr 7, 2022Common StockSSaleDisposed−100$277.02−$27,7021,875Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 6, 2022Common StockMOption exerciseDisposed−2,000$0.00$014,000Direct
Apr 7, 2022Common StockMOption exerciseDisposed−2,000$0.00$012,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Referenced by the price of 7 transactions in Table I.

F3

Open market sales reported on this line occurred at a weighted average price of $270.67 (range $270.42 to $270.88).

Referenced by the price of 1 transaction in Table I.

F4

Open market sales reported on this line occurred at a weighted average price of $271.78 (range $271.43 to $272.33).

Referenced by the price of 1 transaction in Table I.

F5

Open market sales reported on this line occurred at a weighted average price of $272.84 (range $272.56 to $272.97).

Referenced by the price of 1 transaction in Table I.

F7

Open market sales reported on this line occurred at a weighted average price of $272.76 (range $272.50 to $273.28).

Referenced by the price of 1 transaction in Table I.

F8

Open market sales reported on this line occurred at a weighted average price of $273.78 (range $273.52 to $273.98).

Referenced by the price of 1 transaction in Table I.

F9

Open market sales reported on this line occurred at a weighted average price of $275.26 (range $274.64 to $275.43).

Referenced by the price of 1 transaction in Table I.

F10

Open market sales reported on this line occurred at a weighted average price of $276.37 (range $275.94 to $276.82).

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)